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The Association Between Cholecystectomy, Metabolic
Syndrome, and Nonalcoholic Fatty Liver Disease:
A Population-Based Study
Carmen S. S. Latenstein, BSc1, Louise J. M. Alferink, MD2, Sarwa Darwish Murad, MD, PhD2, Joost P. H. Drenth, MD, PhD3,
Cornelis J. H. M. van Laarhoven, MD, PhD1 and Philip R. de Reuver, MD, PhD1
OBJECTIVES: Obesity is a risk factor for several phenotypes such as gallstones, metabolic syndrome (MS), and
nonalcoholic fatty liver disease (NAFLD). It has been suggested that cholecystectomy is a risk factor for
metabolic abnormalities and NAFLD. We aimed to determine whether cholecystectomy is associated
with MS or NAFLD in a Dutch population-based study.
METHODS: TheRotterdamStudy is an ongoing prospective population-based cohort.We included participantswho
underwent a liver ultrasound between 2009 and 2014 to assess steatosis. The prevalence of MS and
NAFLD was calculated, and we performed regression analyses relating cholecystectomy with MS and
NAFLD and adjusted for age, sex, study cohort, education level, physical activity, energy intake, time since
cholecystectomy, body mass index, presence of hypertension, diabetes mellitus, and steatosis/MS.
RESULTS: We included 4,307 participants (57.5% women, median age 66.0 years [interquartile range 58–74]).
In total, 265 participants (6.2%) underwent a cholecystectomy. The median age at the time of
cholecystectomywas57.0 years (47.5–66.5), and themedian time fromcholecystectomy to imaging of
the liver was 10.0 years (0.5–19.5). The prevalence of MS in participants with cholecystectomy was
67.2% and 51.9% in participants without cholecystectomy (P < 0.001). Ultrasound diagnosed
moderate/severe NAFLD was present in, respectively, 42.7% and 34.2% of the participants (P5
0.008). After multivariable adjustments for metabolic factors, cholecystectomy was no longer
associated with the presence of MS or NAFLD.
DISCUSSION: The prevalence of MS and NAFLD is higher in participants after cholecystectomy. However, our trial
shows that cholecystectomymay not be independently associated with the presence of MS and NAFLD
after correction for metabolic factors.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A279, http://links.lww.com/CTG/A280
Clinical and Translational Gastroenterology 2020;11:e00170. https://doi.org/10.14309/ctg.0000000000000170
INTRODUCTION
To date, a cholecystectomy is considered a relatively innocuous
procedure. However, Ruhl and Everhart showed an independent
association of nonalcoholic fatty liver disease (NAFLD) with
cholecystectomy, in a large population-based study in the Unites
States (1). It has been hypothesized that gallstonesmay be an early
biomarker signaling the development of metabolic syndrome
(MS) and liver steatosis even before (morbid) obesity is present.
On the other hand, it is conceivably that cholecystectomy actually
drives the development of NAFLD (2), which would increase the
unknown medical and financial burden of this presumably low-
risk operation significantly.
Inflammation associated with NAFLD may result in liver
damage, liverfibrosis, and eventually cirrhosis (3). Aggravation of
steatosis is multifactorial; multiple risk factors such as insulin
resistance,MS, and interaction between cytokines and adipokines
eventually cause cirrhosis (4,5). Several preclinical studies showed
that cholecystectomy affects the enterohepatic bile salt circulation
and attendant signaling via the bile salt receptors engaged in
metabolichomeostasis (6–8).Thismay suggest that cholecystectomy
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is a biomarker for metabolic abnormalities via bile acid–induced
changes in the enterohepatic circulation and is indeed another
“fellow traveler” with, or another biomarker for NAFLD. The US
study showed a stronger association of NAFLD with cholecystec-
tomy compared with the presence of gallstones alone and suggests
that cholecystectomy may be a risk factor for NAFLD itself (1).
In the Netherlands, the prevalence of gallstone disease, MS,
and NAFLD is, respectively, 5%–30%, 14%, and 22% and similar
with other western countries (9–14). To date, the exact associa-
tion between cholecystectomy, MS, and NAFLD has not been
clarified; that is, current research is conflicting and reported
results needs validation. We therefore aimed to determine
whether cholecystectomy is associated with MS and NAFLD in
a large ongoing Dutch prospective population cohort.
METHODS
Study population
This study is an analysis of the Rotterdam Study—a large ongoing
population-based cohort of participants aged 45 years and older
living in a suburb of Rotterdam, the Netherlands. The rationale
and design of this population-based study are previously de-
scribed (15). For our study, all participants in the Rotterdam
Study cohort I, visit 5 (participants$75 years) and cohort III, visit
2 (participants $50 years) were included. These participants
visited the research center between March 2009 and June 2014.
They had their first visit to the study center between 1989–1993
and 2006–2008, respectively (Figure 1). To exclude participants
with secondary steatosis, participants with viral hepatitis B or C,
alcoholic misuse (in man.3 and women.2 glasses per day), or
participants who use steatogenic medication (i.e., methotrexate, ta-
moxifen, amiodarone, and systemic corticosteroid), for example, for
autoimmune hepatitis, were excluded from the NAFLD-group.
Participants with a diagnosed autoimmune hepatitis were excluded
as well. The Rotterdam Study has been approved by the institutional
review board (Medical Ethics Committee) of the Erasmus MC
UniversityMedicalCenterRotterdamandby the reviewboardof the
Dutch Ministry of Health, Welfare and Sports. Written informed
consent was obtained from all participants. This research was per-
formed in accordance with the ethical standards of the updated
tenets of the Declaration of Helsinki of 2013. The results will be
presented according to the Strengthening the Reporting of Obser-
vational studies in the Epidemiology (STROBE) guidelines.
Cholecystectomy
Participants in cohort I were asked for their surgical history at
time of inclusion in the cohort. However, participants in cohort
III were not asked for their complete surgical history. We there-
fore additionally linked the data of the Rotterdam study to our
nationwide pathology database (PALGA), which has a nation-
wide coverage from 1991 onward. The database was searched for
cholecystectomies in participants of cohort I and III. Of all par-
ticipants with a cholecystectomy, the year of cholecystectomywas
available from the surgical history or PALGA-database.
Nonalcoholic fatty liver disease
A certified and experienced technician performed the abdominal
ultrasounds with a Hitachi HI VISION 900 between 2009 and
2014. All images were re-evaluated by a single hepatologist. Di-
agnosis of steatosis was determined dichotomously as the pres-
ence or absence of a hyperechogenic liver parenchyma, that is,
moderate or severe steatosis (16). NAFLDwas defined as steatosis
on ultrasound with the absence of secondary causes of steatosis
(as abovementioned).
Metabolic syndrome
MS was defined according to the Alberti-2009 method (17). MS
was diagnosed when at least 3 of the following risk factors were
present: (i) abdominal obesity, defined as WC$ 102 cm in men
and$ 88 cm in women, (ii) serum triglycerides$150mg/dL (1.7
mmol/L) or drug treatment for elevated triglycerides, (iii) serum
high-density lipoprotein cholesterol#40 mg/dL (1.0 mmol/L) in
men and#50 mg/dL (1.3 mmol/L) in women, or drug treatment
for low high-density lipoprotein cholesterol, (iv) blood pressure
$130/85 mm Hg or drug treatment for elevated blood pressure,
and (v) fasting plasma glucose$100mg/dL (5.6mmol/L) or drug
treatment for elevated blood glucose. Participants with missing
data regardingMS or unreliable high or low values were excluded.
Diabetes mellitus (DM) was defined as a fasting plasma glu-
cose $110 mg/dL or drug treatment for elevated blood glucose,
and hypertension was defined as a systolic blood pressure
$140 mm Hg, a diastolic blood pressure $90 mm Hg, or drug
treatment for elevated blood pressure.
Biochemistry and additional covariates
Fasting blood samples were collected. Blood lipids and fasting
plasma glucose were measured using automatic enzyme proce-
dures (Roche Diagnostic GmbH, Mannheim, DE). Hepatitis B
surface antigen and antihepatitis C virus were measured by an
automatic immunoassay (Roche Diagnostic GmbH). De-
mographics, education level,medical history, comorbidities, physical
activity, and smoking were obtained during a home interview. Total
energy intake and alcohol use were assessed using a validated food
frequency questionnaire (18). Medication use was obtained from an
automatic linkage to the pharmacies. Anthropometric measure-
ments were performed by well-trained research assistants, and
weight, height, and waist circumference were measured.
Statistical analyses
Characteristics of participants were stratified by history of cho-
lecystectomy. Continuous, normally distributed data were pre-
sented as mean with the SD and continuous non-normal
distrusted data as median with the interquartile range (IQR).
Dichotomous data were summarized as frequencies and pro-
portions. Comparison of clinical characteristics between both
groups was performed using the x2 test for dichotomous data, the
Student t test for normally distributed continuous data, and the
Mann-Whitney U test for skewed continuous data.
Univariate logistic regression analyses were performed to ex-
amine the association between cholecystectomy and MS and the
association between cholecystectomy and NAFLD. The re-
gression analysis was first performed in a univariable fashion and
second with multivariable adjustments. These adjustments were
made by the inclusion of age, sex, Rotterdam Study cohort, ed-
ucation level, physical activity, total energy intake, time since
cholecystectomy more than 10 years, presence of hypertension,
presence of DM, and body mass index (BMI); in the analysis for
MS, the presence of steatosiswas included in themodel, and in the
analysis for steatosis, the presence of MS was included. Correla-
tion and multicollinearity between cholecystectomy, MS, and
NAFLD were tested. In addition, interaction between the cova-
riables was tested. The outcome of the univariable andmultivariable
Clinical and Translational Gastroenterology VOLUME 11 | APRIL 2020 www.clintranslgastro.com
LI
VE
R
Latenstein et al.2
analyses were presented as an odds ratio (OR) and 95% confidence
interval (CI).
Several sensitivity analyses were performed. We stratified by
sex because of sex differences in the prevalence of cholecystec-
tomy, MS, and NAFLD. To test the robustness of our data,
analyses were performed stratified by cohort, and second, data
were analyzed in a separate group of nonoverweighed partic-
ipants (BMI,25).
Associations with a P value less than 0.05 will be considered
statistically significant. Allmissing valueswere considered to be at
random and were excluded from the analyses. Analyses were
performed using SPSS statistics version 25.0 (IBM).
RESULTS
Study population
Between March 2009 and January 2011 2,147 participants from
the Rotterdam Study cohort I and between March 2012 and June
2014 3,122 participants from Rotterdam Study cohort III visited
the research center. In total, 904 participants were excluded be-
cause there were no data available regarding abdominal ultra-
sound. Moreover, 58 participants were excluded with missing or
unreliable data regarding MS. Hence, in this analysis, 4,307 par-
ticipants were included (Figure 2). Six hundred fifty-seven par-
ticipants were excluded for the analyses regarding NAFLD
because they fulfilled the criteria for secondary steatosis. None of
the included participants had a diagnosed autoimmune hepatitis.
So, all data regarding NAFLD were studied in 3,650 participants.
Of the included participants, 57.5% was women, median age
was 66.0 years (IQR 58–74), andmean BMI was 27.56 4.4 kg/m2
(Table 1). MS was present in 2,278 participants (52.9%). Steatosis
was present in 35.4% (n 5 1,525), and NAFLD in 34.8% (n 5
1,269) (Table 2).
Cholecystectomy
In 265 participants (6.2%), a cholecystectomy was performed.
The median age at time of cholecystectomy was 57.0 years
(47.5–66.5). The median interval between cholecystectomy and
liver imaging was 10.0 years (0.5–19.5). In Table 1, 265 partic-
ipants with cholecystectomy were compared with the 4,042 par-
ticipants without cholecystectomy. Participants with
cholecystectomy were older, more often women and (ex-)
smokers, used less alcohol, had a lower physical activity and en-
ergy intake, and a higher BMI as compared to participants
without cholecystectomy. The prevalence of MS in participants
with cholecystectomy was 67.2% (n 5 178) and 51.9% in par-
ticipants without cholecystectomy (n5 2,099) (P , 0.001). The
prevalence of DM was 19.0% in participants with cholecystec-
tomy and 12.2% in participants without cholecystectomy (P 5
0.001); hypertension was present in 78.4% of participants with
Figure1.Available data on time line. Participants in cohort I and cohort III of theRotterdamStudywere included. Participants in cohort I had their first visit to
the study center between 1989 and 1993. We included data from visit 5 (2009–2011). Participants in cohort III had their first visit to the study center
between 2006 and 2008. We included data from visit 2 (2012–2014).
Figure 2. Flowchart of inclusion. Participants were included from cohort I
and cohort III. Participants withmissing ultrasound ormetabolic syndrome
data were excluded. RS, Rotterdam Study.
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cholecystectomy and in 69.2% of participants without cholecys-
tectomy (P5 0.002). NAFLD was present in, respectively, 42.7%
and 34.2% (P 5 0.008) (Table 2).
Differences in characteristics between participants with and
without MS and NAFLD are shown in Table 1, Supplementary
Digital Content 1, http://links.lww.com/CTG/A279, and Table 2,
http://links.lww.com/CTG/A280, respectively.
Cholecystectomy and metabolic syndrome
Cholecystectomy was associated with MS in univariable logistic
regression analysis (Table 3). After multivariable adjustments for
metabolic factors (steatosis, hypertension, andDM), cholecystectomy
was no longer associated with MS (Table 4). Steatosis and MS were
significantly correlated (r5 0.309, P, 0.001); however, there was no
multicollinearity (VIF 1.1). Interactions between covariables and
cholecystectomy were tested and found to be not significant.
Cholecystectomy and NAFLD
Cholecystectomy was associated with NAFLD in univariable lo-
gistic regression analysis (Table 3). However, after multivariable
adjustments for metabolic factors, this association was no longer
significant (Table 4). DM and hypertension had a significant in-
teraction (OR 0.422, 95% CI 0.181–0.987, P 5 0.047). No other
interactions between covariables and cholecystectomy were found.
Table 1. Comparison participants without cholecystectomy and with cholecystectomy on study characteristics
Total, N 5 4,307 No cholecystectomy, N5 4,042 Cholecystectomy, N 5 265 P value
Age (yr) 66.0 (58–74) 65.0 (57–75) 75.0 (66–84) ,0.001
Sex—female 57.5 56.4 74.3 ,0.001
Racea—caucasian 97.4 97.3 98.7 0.187
BMI (kg/m2) 27.5 6 4.4 27.4 6 4.4 29.4 6 5.0 ,0.001
Weight N/O/Ob 29.3/46.7/24.0 30.2/46.7/23.1 16.2/46.8/37.0 ,0.001
Education L/I/H 47.3/29.6/22.7 47.1/29.5/22.9 50.6/30.6/18.9 0.280
Smokingb N/C/P 33.9/41.8/24.3 33.9/41.2/24.8 33.6/50.6/15.8 0.002
Alcohol (units/d) 0.68 (0.1–1.5) 0.74 (0.1–1.6) 0.19 (0.1–0.7) ,0.001
Activityc (MET hr/wk) 38.5 (8.7–68.4) 39.7 (9.6–69.8) 22.5 (0.1–45.5) ,0.001
Energy intake 2,187 6 837.7 2,219.9 6 820.8 1,906.8 6 865.8 ,0.001
Age at cholecystectomy NA 57.0 (47.5–65.5)
Time since cholecystectomy (yr) NA 10.0 (0.5–19.5)
Data is presented as mean (6SD), median (IQR) or percentage. All P values less than 0.05 are in bold.
BMI, body mass index; IQR, inter quartile range; L/I/H, low/intermediate/high; MET, metabolic equivalent of task; NA, not applicable; N/C/P, never/current/past; N/O/Ob,
normal/overweight/obese.
aData according race were available for 3,923 participants.
bData according smoking were available for 4,069 participants.
cData according activity were available for 3,671 participants.
Table 2. Comparison participants without cholecystectomy and with cholecystectomy on metabolic syndrome and liver imaging
Total, N 5 4,307 No cholecystectomy, N 5 4,042 Cholecystectomy, N 5 265 P value
Diabetes mellitus 12.6 12.2 19.0 0.001
Hypertension 69.7 69.2 78.4 0.002
Waist circumferencea 44.3 42.9 64.5 ,0.001
Fasting plasma glucose .100 mg/dL 47.7 47.2 54.4 0.025
Triglycerides.150 mg/dL 46.6 46.1 54.0 0.013
HDL-Cb 45.4 44.9 52.8 0.012
Blood pressure $130/85 mm Hg 80.3 79.9 87.5 ,0.001
Metabolic syndrome 52.9 51.9 67.2 ,0.001
Steatosis 35.4 34.9 43.0 0.007
NAFLDc 34.8 34.2 42.7 0.008
Data are presented as percentages. All P values less than 0.05 are in bold.
HDL-C, high-density lipoprotein cholesterol; NAFLD, nonalcoholic fatty liver disease.
aFemale waist circumference of. 88 cm and male waist circumference of .120 cm.
bFemale HDL-C of ,50 mg/dL and male HDL-C of ,40 mg/dL.
cNAFLD was measured in 3,650 participants.
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Secondary analysis
In the multivariable regression analyses, sex was independently
associated with the presence of MS (sex, women: OR 0.810, 95%
CI 0.672–0.975, P 5 0.026) and also for with the presence of
NAFLD after correction for the metabolic factors (sex, women:
OR 0.794 95% CI 0.644–0.978, P 5 0.030). We performed the
multivariable regression analyses separately for men and women.
In men, a trend toward an association between cholecystectomy
and MS was found in multivariable logistic regressions (OR
2.239, 95% CI 0.923–5.434, P 5 0.075). Multivariable
regressions in women showed no significant association be-
tween cholecystectomy and MS (OR 1.320, 95% CI
0.686–2.537, P 5 0.450). In line with the main analysis, no
significant association was found in multivariable analyses
between cholecystectomy and NAFLD stratified by sex (men:
OR 0.912, 95% CI 0.317–2.624, P5 0.864, women: OR 1.070,
95% CI 0.572–1.999, P 5 0.833).
Sensitivity analysis
Separate multivariable analyses for cohort I (age$75 years) and
cohort III (age $50 years) demonstrated no significant associa-
tion between cholecystectomy andMS in cohort I (OR 1.146, 95%
CI 0.547–2.402, P 5 0.718); however, the association between
cholecystectomy and MS in cohort III showed a trend toward
association (OR 2.029, 95% CI 0.958–4.295, P 5 0.064). For
NAFLD, no significant associations were found (cohort I OR
1.126, 95%CI 0.505–2.511,P5 0.772; cohort III OR1.003 95%CI
0.489–2.057, P 5 0.994).
Analyzing only participants with a normal BMI (#25 kg/m2),
resulted in similar findings, no significant association between
cholecystectomy andMS, or NAFLD, was found in multivariable
regression analyses (MS: OR 0.811, 95% CI 0.230–2.862, P 5
0.745, NAFLD: OR 1.026, 95% CI 0.604–1.744 P 5 0.924).
DISCUSSION
The results of this study show that cholecystectomy is not in-
dependently associatedwith the presence ofMS andNAFLDafter
correction for metabolic factors. Although the prevalence of
NAFLD in this population is high (34.8%) and is even higher in
participants with a previous cholecystectomy (42.7%), we found
that after adjustment for multiple metabolic factors cholecys-
tectomywas not associated with the presence of NAFLD nor with
the presence of MS.
These results are at oddswith the findings of population-based
study withmore than 12,000 participants in the United States (1).
These researchers found an independent association of NAFLD
with cholecystectomy after adjustment for multiple metabolic
factors in a large population-based study of the NHANES. Al-
though their study was methodologically different, it screened all
patients for gallstones with ultrasound and compared
Table 3. Univariable logistic regressions with metabolic syndrome and NAFLD as dependent variable
Univariable regression with metabolic syndrome as
outcome N5 4,307
Univariable regression with NAFLD as outcome
N 5 3,650
OR 95% CI P value OR 95% CI P value
Age 1.03 1.02–1.03 ,0.001 1.00 0.99–1.01 0.440
Sex—female 0.79 0.70–0.89 ,0.001 0.95 0.83–1.10 0.507
Rotterdam study cohort I 1.41 1.24–1.60 ,0.001 1.04 0.90–1.97 0.602
Caucasiana 1.29 0.87–1.92 0.205 1.49 0.94–2.37 0.092
Education—low 1.58 1.36–1.85 ,0.001 1.67 1.39–2.01 ,0.001
Smokingb 1.22 1.04–1.44 0.017 1.15 0.96–1.39 0.137
Alcohol 0.99 0.95–1.04 0.744 0.99 0.89–1.10 0.788
Physical activityc 0.99 0.99–0.99 ,0.001 0.99 0.99–0.99 ,0.001
Total energy intake 0.83 0.76–0.90 ,0.001 0.88 0.80–0.97 0.013
BMI 1.26 1.23–1.28 ,0.001 1.27 1.24–1.29 ,0.001
Cholecystectomy 1.89 1.46–2.47 ,0.001 1.43 1.10–1.87 0.008
Age at time of cholecystectomy 1.01 0.99–1.02 0.434 1.00 0.99–1.01 0.442
Cholecystectomy. 10 years ago 1.92 1.34–2.77 ,0.001 1.77 1.23–2.53 0.002
Metabolic syndrome NA NA NA 4.00 3.45–4.65 ,0.001
Diabetes mellitus 14.22 10.24–19.74 ,0.001 3.78 3.09–4.63 ,0.001
Hypertension 5.77 4.98–6.68 ,0.001 4.00 3.45–4.65 ,0.001
Steatosis 3.96 0.35–4.57 ,0.001 NA NA NA
NAFLD 4.00 3.45–4.65 ,0.001 NA NA NA
All P values less than 0.05 are in bold.
BMI, body mass index; CI, confidence interval; NA, not applicable; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio.
aData according race were available for 3,923 participants.
bData according smoking were available for 4,069 participants.
cData according activity were available for 3,671 participants.
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participants with cholecystectomy with participants without
gallstone disease (no gallstones, no cholecystectomy). Second,
they analyzed participants with gallstones separately and found
a significant association with NAFLD in men only. The associa-
tion between gallstone disease andNAFLDhas been confirmed in
a systematic review including 12, mostly cross-sectional, studies
(19). This study showed thewide range in prevalence of gallstones
disease and NAFLD from 5% to 50%. Six studies compared
patients with gallstones or cholecystectomy with patients with no
gallstone disease at all. Of these studies, 2 did not show that
gallstone disease was independently associated with NAFLD
(20,21), whereas 4 did (22–25). All studies adjusted for different
covariates as potential confounders. None of the 12 included
studies compared subjects with cholecystectomy to subjects
without cholecystectomy. Only one other study, comparable with
ours, did comparing cholecystectomy to without cholecystec-
tomy and found similar results; a significant association between
cholecystectomy andNAFLDwas found, but after adjustment for
factors such as BMI, glucose, lipid spectrum, blood pressure, and
liver function, cholecystectomywas not independently associated
withNAFLD (26). Several studies showed an association between
gallstone disease and MS; however, they all used different con-
founder correction (27,28).
MS and NAFLD are highly prevalent in patients with gall-
stones or cholecystectomy; these conditions share common risk
factors such as overweight, hypertension, high cholesterol, and
DM and are all related to lifestyle (14,29). General practitioners
and surgeons should be aware of these lifestyle-related
conditions.
As our research counters previous reports on the association
between cholecystectomy and NAFLD, prospective clinical data
are needed. In such a longitudinal study, incidence ofNAFLDand
MS could be assessed in patients with gallstones before and after
cholecystectomy. The alterations in the dynamics of bile salt
recirculation could underly the metabolic anomalies in chole-
cystectomized patients andneeds to be tested (8,30). The presence
of cholesterol gallstones is, similar to NAFLD, a hepatic mani-
festation of MS (31,32). Because it is shown that cholecystectomy
Table 4. Stepwise logistic regression models with metabolic syndrome and NAFLD as dependent variables
Metabolic syndrome, N5 4,307 OR 95% CI P value NAFLD, N5 3,650 OR 95% CI P value
Step 1 Step 1
Cholecystectomy 1.82 1.39–2.38 ,0.001 Cholecystectomy 1.44 1.10–1.88 0.008
Age 1.04 1.03–1.05 ,0.001 Age 1.00 0.99–1.02 0.607
Sex—female 0.76 0.67–0.86 ,0.001 Sex—female 0.94 0.82–1.08 0.361
Rotterdam Study cohort I 0.68 0.54–0.86 0.001 Rotterdam Study cohort I 0.96 0.74–1.24 0.961
Step 2 Step 2
Cholecystectomy 1.94 1.22–3.08 0.005 Cholecystectomy 1.46 0.91–2.34 0.117
Age 1.03 1.02–1.05 ,0.001 Age 1.00 0.99–1.02 0.729
Sex—female 0.69 0.59–0.81 ,0.001 Sex—female 0.81 0.67–0.97 0.023
Rotterdam Study cohort I 0.77 0.58–1.03 0.074 Rotterdam Study cohort I 0.93 0.67–0.29 0.659
Education—low 1.42 1.17–1.72 ,0.001 Education—low 1.83 1.45–2.32 ,0.001
Physical activity 0.99 0.99–0.99 ,0.001 Physical activity 0.99 0.99–0.99 0.001
Energy intake 0.86 0.78–0.95 0.002 Energy intake 0.91 0.81–1.02 0.101
Cholecystectomy .10 years ago 0.74 0.39–1.40 0.351 Cholecystectomy .10 years ago 1.25 0.67–2.39 0.495
Step 3 Step 3
Cholecystectomy 1.16 0.86–2.46 0.158 Cholecystectomy 1.04 0.62–1.77 0.874
Age 1.01 0.99–1.03 0.143 Age 0.99 0.98–1.01 0.537
Sex—female 0.81 0.67–0.98 0.026 Sex—female 0.79 0.64–0.98 0.030
Rotterdam Study cohort I 1.17 0.92–1.39 0.062 Rotterdam Study cohort I 1.20 0.83–1.73 0.328
Education—low 1.04 0.83–1.31 0.716 Education—low 1.45 1.11–1.89 0.006
Physical activity 0.99 0.99–1.00 0.067 Physical activity 0.99 0.99–1.00 0.319
Energy intake 0.92 0.82–1.03 0.151 Energy intake 1.05 0.92–1.19 0.482
Cholecystectomy .10 years ago 0.73 0.35–1.55 0.414 Cholecystectomy .10 years ago 1.01 0.48–2.14 0.982
Hypertension 4.34 3.51–5.37 ,0.001 Hypertension 1.03 0.80–1.33 0.831
Diabetes mellitus 8.53 5.59–13.03 ,0.001 Diabetes mellitus 1.99 1.48–2.67 ,0.001
Steatosis 1.95 1.60–2.38 ,0.001 Metabolic syndrome 2.01 1.61–2.51 ,0.001
BMI 1.18 1.15–1.21 ,0.001 BMI 1.24 1.21–1.28 ,0.001
All P values less than 0.05 are in bold.
BMI, body mass index; CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; OR odds ratio.
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is a mediocre solution for the treatment of patients with ab-
dominal pain and gallstones, wemay need to rethink our practice
in patients with symptoms all related to the same metabolic
changes (33).
The pathophysiology of steatosis is multifactorial, in which
insulin resistance is an important factor (5). The risk of DM type 2
is higher in patients with NAFLD than in those without NAFLD
(Supplementary Digital Content 2, http://links.lww.com/CTG/
A280) (34). Insulin resistance contributes to the development and
progression of NAFLD, by increasing de novo lipogenesis, by de-
creasing insulin suppression of lipolysis, and subconsequently in-
directly by increasing the free fatty acids flux to the liver (35–37).
More recently, an increasing number of studies are performed to
investigate the influence of insulin resistance on the development
of cholesterol gallstones. A study in pregnant women concluded
that insulin resistance is a risk factor for incident gallbladder sludge
and stones, even after adjustment for BMI (38). Experimental
studies describe that insulin resistance decreases cholesterol ab-
sorption in the intestine and increases cholesterol synthesis and
production of very low-density lipoprotein (39,40). A recent study
concludes that hepatic insulin resistance also decreases expression
of enzymes for the bile acid synthesis and produces partial re-
sistance to the Farnesoid-X receptor, resulting in a lithogenic bile
salt profile (41). Finally, research shows that insulin resistance
causes abnormal motility of the gallbladder (42).
We hypothesize that cholecystectomy changes the enter-
ohepatic circulation. Continuous secretion of bile causes a higher
exposure of bile acids to peripheral which could result in a dif-
ferent lipid and glucose metabolism (7,43,44), resulting in in-
creased BMI, MS, and development of NAFLD. Because BMI,
glucose, and lipids change after cholecystectomy, NAFLD is not
associated with cholecystectomy after correction for metabolic
factors. Furthermore, a decrease of FGF-19 after cholecystectomy
resulting in altered lipid, glucose, and energy metabolism could
also have the outcome of an increased BMI and development of
NAFLD (8).
This study comes with strengths and limitations. Strengths of
our study are the large number of subjects and adjustment for
many available metabolic variables, and the follow-up between
cholecystectomy and ultrasound was large in many subjects.
Moreover, sensitivity analyseswere performed to show consistency
in data. The largest limitation of this study is the cross-sectional
design; ideally, variables were available before and after cholecys-
tectomy; however, long-term longitudinal data on BMI, diabetes,
and liver status in cholecystectomy patients are lacking. Further-
more, based on the available data,we could notmake a difference in
participants with gallstones and without gallstones. Finally, MRI
for the diagnosis of NAFLD was not available in the Rotterdam
Study, mainly because of the associated costs in such a large study
population (45). Invasive tests (as liver biopsy)were not performed
because of the ethical concerns. Therefore, NAFLDwas diagnosed
by ultrasound, which has limitations. Mild, moderate, and severe
steatosis could not reliably be separated, that is why we have di-
chotomized into no steatosis/steatosis, the risk is that we exclude
mild steatosis, but the question is how clinically relevant this is if
you have ,30% lipid droplets. Because inter-reader variability is
important in the interpretation of ultrasounds, all images were re-
evaluated by a single hepatologist. It could well be that many
patients with mild steatosis were not included in the NALFD
group. Therefore, it may be that results are only representative for
moderate–severe steatosis.
In conclusion, MS and NAFLD are common in western
populations and are more prevalent in patients with a history
of cholecystectomy. However, in contrast to previous studies
in our trial, cholecystectomy does not seem independently
associated with the presence of MS or moderate/severe
NAFLD, in which other metabolic factors may play a more
dominant role.
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Study Highlights
WHAT IS KNOWN
3 Gallstones, MS, and NAFLD are associated diseases.
3 Cholecystectomy is suggested to be a risk factor for NAFLD.
WHAT IS NEW HERE
3 MSandNAFLD aremore prevalent in patients with a history of
cholecystectomy, compared with patients without a history of
cholecystectomy.
3 In contrast to previous studies, cholecystectomy is not
independently associated with MS or NAFLD after correction
for multiple metabolic factors.
TRANSLATIONAL IMPACT
3 FLD and gallstone disease share common metabolic risk
factors such as overweight, hypertension, high cholesterol,
diabetes mellitus, and are all related to lifestyle. The
relationship between cholecystectomy and NAFLD is
complex and needs further investigation in order to fully
inform patients about the long-term consequences of
a cholecystectomy.
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